Ghent University Academic Bibliography

Advanced

Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study

Stéphanie Laurent UGent, Els Monsaert, Tom Boterberg UGent, A Demols, I Borbath, M Polus, A Hendlisz, Bernard de Hemptinne UGent, C Mahin and P Scalliet, et al. (2009) ANNALS OF ONCOLOGY. 20(8). p.1369-1374
abstract
Patients and methods: Twenty-two patients with locally advanced pancreatic (n = 17) or biliary tract cancer (n = 5) were included. They received two cycles of gemcitabine/oxaliplatin followed by 5 weeks of RT in combination with a weekly fixed dose gemcitabine and an escalating dose of oxaliplatin from 40 up to 70 mg/m(2). National Cancer Institute-Common Toxicity Criteria 3.0 was used to score weekly the treatment-related toxicity. Results: The patients treated at a dose of 40 mg/m(2) of oxaliplatin had no dose-limiting toxicity. At 50 mg/m(2), two patients developed grade 4 thrombocytopenia. Nine patients received 60 mg/m(2), one developed grade 4 thrombocytopenia. Grade 4 thrombocytopenia in two patients and grade 3 diarrhea in one patient were observed with 70 mg/m(2). Median time to progression was 8 months and median overall survival was 17 months. Conclusions: RT in combination with gemcitabine and oxaliplatin is feasible in patients with locally advanced pancreaticobiliary cancer. The reported time to progression underlines the potential activity of this regimen. The dose of 60 mg/m(2) of oxaliplatin can be considered as the recommended dose.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
journal title
ANNALS OF ONCOLOGY
Ann. Oncol.
volume
20
issue
8
pages
1369 - 1374
Web of Science type
Article
Web of Science id
000268806700010
JCR category
ONCOLOGY
JCR impact factor
5.647 (2009)
JCR rank
19/163 (2009)
JCR quartile
1 (2009)
ISSN
0923-7534
DOI
10.1093/annonc/mdp005
language
English
UGent publication?
yes
classification
A1
id
824749
handle
http://hdl.handle.net/1854/LU-824749
date created
2010-01-11 12:05:49
date last changed
2010-01-21 15:42:25
@article{824749,
  abstract     = {Patients and methods: Twenty-two patients with locally advanced pancreatic (n = 17) or biliary tract cancer (n = 5) were included. They received two cycles of gemcitabine/oxaliplatin followed by 5 weeks of RT in combination with a weekly fixed dose gemcitabine and an escalating dose of oxaliplatin from 40 up to 70 mg/m(2). National Cancer Institute-Common Toxicity Criteria 3.0 was used to score weekly the treatment-related toxicity.

Results: The patients treated at a dose of 40 mg/m(2) of oxaliplatin had no dose-limiting toxicity. At 50 mg/m(2), two patients developed grade 4 thrombocytopenia. Nine patients received 60 mg/m(2), one developed grade 4 thrombocytopenia. Grade 4 thrombocytopenia in two patients and grade 3 diarrhea in one patient were observed with 70 mg/m(2). Median time to progression was 8 months and median overall survival was 17 months.

Conclusions: RT in combination with gemcitabine and oxaliplatin is feasible in patients with locally advanced pancreaticobiliary cancer. The reported time to progression underlines the potential activity of this regimen. The dose of 60 mg/m(2) of oxaliplatin can be considered as the recommended dose.},
  author       = {Laurent, St{\'e}phanie and Monsaert, Els and Boterberg, Tom and Demols, A and Borbath, I and Polus, M and Hendlisz, A and de Hemptinne, Bernard and Mahin, C and Scalliet, P and Van Laethem, JL and Peeters, Marc},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  language     = {eng},
  number       = {8},
  pages        = {1369--1374},
  title        = {Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study},
  url          = {http://dx.doi.org/10.1093/annonc/mdp005},
  volume       = {20},
  year         = {2009},
}

Chicago
Laurent, Stéphanie, Els Monsaert, Tom Boterberg, A Demols, I Borbath, M Polus, A Hendlisz, et al. 2009. “Feasibility of Radiotherapy with Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma: a Prospective Dose Finding Phase I-II Study.” Annals of Oncology 20 (8): 1369–1374.
APA
Laurent, Stéphanie, Monsaert, E., Boterberg, T., Demols, A., Borbath, I., Polus, M., Hendlisz, A., et al. (2009). Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. ANNALS OF ONCOLOGY, 20(8), 1369–1374.
Vancouver
1.
Laurent S, Monsaert E, Boterberg T, Demols A, Borbath I, Polus M, et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. ANNALS OF ONCOLOGY. 2009;20(8):1369–74.
MLA
Laurent, Stéphanie, Els Monsaert, Tom Boterberg, et al. “Feasibility of Radiotherapy with Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma: a Prospective Dose Finding Phase I-II Study.” ANNALS OF ONCOLOGY 20.8 (2009): 1369–1374. Print.